The challenge of spotting cancers in children

Georgia Hillman

Georgia was diagnosed with Wilms’ tumour

One Sunday evening in 2008, after giving her one-year-old daughter a bath, Ruth Hillman noticed Georgia’s tummy felt firmer than usual.

Alarm bells began to ring.

By Wednesday, after seeing several different doctors, Ruth and her husband Ben were told Georgia had a tumour. Further tests showed that it was a Wilms’ tumour – a form of kidney cancer – and Georgia needed intensive treatment.

Georgia’s story is ultimately a happy one – she’s now a healthy five-year-old, and recently started school. Her treatment – surgery and chemotherapy – means she’s among some 33,000 people alive in the UK today who beat cancer in childhood. Although progress in some cancer types has been slow, overall survival rates are now at an all-time high.

But could they be even higher? In the end, Georgia was diagnosed in time, but others aren’t so fortunate. And, as in adults, cancer treatments in children are generally less effective when the disease is spotted late.

They’re also often more intense. As a result, survivors can have long-term disabilities – and with more lives being saved, this has meant an ever-greater focus on how we manage cancers in the youngest members of society.

The problem is that cancers in children are rare, and their symptoms are hard to tell apart from a whole range of more common problems. The average GP will only ever see a single case in their entire career – if at all. And for parents, they may never suspect that an ache or a pain could be something more sinister than childhood’s day-to-day rough and tumble.

In this blog post, we’ll take a look at the issues surrounding spotting cancers in children, and what’s going on to try to improve things.

Continue reading

Introducing our latest arsenal in the fight against cancer

A scientist in the lab

Our committee has invested £23million in new research

Thanks to the generosity of our supporters, we’re able to spend hundreds of millions of pounds every year on life-saving cancer research.

And our highly experienced Science Committee makes sure this money goes to fund the most creative, promising and innovative research in the UK.

The committee recently met to decide which pioneering new research projects have what it takes to lead the fight against cancer.

After careful consideration the committee chose to spend over £23million in world class research across a spectrum of work – from screening to trials and cancer biology.

Here are some of the highlights.

Continue reading

“Dear Cancer, I beat you aged eight and today I got my PhD in cancer research”

Dr Vicky Forster in the lab

Dr Vicky Forster at work in the lab

December is Childhood Cancer Awareness month, and it will always be a memorable time for Dr Vicky Forster – but not for the right reasons.

In this inspiring piece for the Children’s Cancer and Leukaemia Group (CCLG) newsletter, Contact, she describes her own experience of cancer as a child and how it motivated her to pursue a career as a cancer researcher. She also tells the story of how a celebratory tweet when she gained her PhD made it around the world. Vicky’s now a scientist at the Northern Institute for Cancer Research – part of our Newcastle Cancer Centre. Thanks to Vicky and the CCLG for allowing us to share her story here.

On Christmas day in 1994, whilst the rest of my family were playing games in the lounge, I was asleep in bed upstairs feeling absolutely exhausted, despite the fact that I had only woken up a few hours previously.  I had been ill for a few weeks with what the doctor thought was a chest infection.  Later that week, when I still wasn’t better, my mum took me to the doctor again who sent me for a blood test.

Vicky aged eight

Vicky aged eight, undergoing cancer treatment

On New Year’s Eve 1994, I was diagnosed with acute lymphoblastic leukaemia and admitted to St. Bartholomew’s hospital in London for a two and a half year program of treatment.   All of my family were extremely shocked about the diagnosis, but we coped – my parents taking it in turns to either be in hospital with me in London, or with my little sister Becky who had just started school back home in Essex.  It was hard being off school for so long at that age, as I really loved being in school, but the teachers at the hospital were incredible for keeping my passion for learning going.

Continue reading

Notes from NCRI conference (day 4)

NCRI banner

That’s all folks!

Before the final day of the conference started, we once again awoke to news stories based on research presented over the last few days.

The BBC led with figures released at the conference showing that the economic cost of cancer tops £15bn a year in the UK. Drawing on the same figures, the Daily Mail highlighted the staggering toll of lung cancer in the UK – £2.4 billion per year – which is more than other common cancers such as breast and bowel.

We agree with their headline that there’s an urgent need to stop younger people from taking up smoking – the major cause of lung cancer.
Continue reading

Imatinib – the dawn of targeted treatments

Mary Bacon was treated with imatinib

Mary Bacon was treated with imatinib for two years after she was diagnosed with CML in 2008

Thirty years ago, we published research that was a key early step in the journey towards the first genetically tailored cancer drug, imatinib (also known as Glivec, or Gleevec in the United States).

This drug changed the landscape, not just for those for whom it was designed – people with chronic myeloid leukaemia – but for cancer treatment as a whole.

Imatinib is unlike the conventional chemotherapy drugs that came before it. Such ‘cytotoxic’ chemo indiscriminately kills rapidly dividing cells. These include the intended target – cancer cells – but also some healthy cells like those lining the gut and mouth and hair follicle cells. Imatinib on the other hand, is specific to a molecule produced by certain cancer cells.

Imatinib featured on the front cover of Time magazine and was hailed as a “magic bullet”.  It was indeed a revolution of its time – after it was approved in 2001, bed-ridden patients who’d been given just months to live were up on their feet and re-energised, thanks to their cancer being eradicated by imatinib.

The story of imatinib – outlined in more detail below – is proof that if you understand the precise abnormality that is driving the cancer, there is hope for a cure. And we are proud that our early laboratory work provided a crucial stepping stone on the road to its development.

Continue reading

New insights into the treatment of childhood leukaemia

Child in hospital

New study about acute lymphoblastic leukaemia

On the surface, the statistics about acute lymphoblastic leukaemia (ALL) are encouraging. Thanks to decades of painstaking research and clinical advances, around eight in 10 children and young adults with the disease are cured.

But for the families of those children who are the ‘two in 10’, this impressive statistic is cold comfort.

That’s why many scientists around the world – including our own – are working hard to ensure even more children are successfully treated.

Today we spotted a huge global study that represents an important step in the fight against ALL. It points to better ways to treat the small number of children who don’t respond to their initial treatment.

We spoke to Cancer Research UK scientist Professor Josef Vormoor about the research, and asked him what he thought of its implications.

Continue reading

Stiliyan Petrov: information about acute leukaemia

Stiliyan Petrov

Aston Villa captain, Stiliyan Petrov

Over the weekend we heard the news that Stiliyan Petrov, captain of Aston Villa football club, has been diagnosed with acute leukaemia.

We wish him the very best of luck, and our thoughts are with his family.

As a result of his diagnosis, we’ve noticed an increase in traffic to our website from people looking for information about his disease.

To help, we’ve pulled together links to our main pages below.

Continue reading